<DOC>
	<DOCNO>NCT01206712</DOCNO>
	<brief_summary>The purpose phase IV clinical trial investigate effect Insulin glargine + metformin treatment vs. sulfonylurea + metformin treatment vs. DPP-4 + metformin treatment vs. healthy volunteer ß-cell function uptake standardized meal .</brief_summary>
	<brief_title>Beta Cell Relieving Cardiovascular Protective Effects LANTUS Treatment Type 2 Diabetes Patients</brief_title>
	<detailed_description>Type 2 diabetes mellitus progressive disease characterise steady loss beta cell function increase proinsulin/insulin ratio . During recent year intact proinsulin topic interest numerous preclinical clinical study patient type 2 diabetes mellitus . Intact proinsulin confirm marker functional beta cell failure predictor increase beta cell loss due apoptosis and/or diminish neogenesis . A number population base study show intact proinsulin strong predictor coronary heart disease diabetic , non-diabetic patient . In clinical trial investigate human proinsulin therapeutic approach treatment diabetes mellitus eight fold increase CVD find treatment human proinsulin compare human regular insulin , indicate thrombo-embolic potential intact proinsulin . In recent investigation association could confirm increased proinsulin plasma concentration severity angiographical characterise CHD . Even exact mechanism proinsulin involve pathogenesis atherosclerosis completely recognize , already show PAI-1 activity increase proinsulin administration vitro , increase evidence atherogenic effect proinsulin might link increase plasminogen activator inhibitor-1 ( PAI-1 ) level subsequent inhibition fibrinolysis augment thrombogenic potency . Treatment sulfonylurea increase intact proinsulin secretion , couple study , sulfonylurea treatment find associate increased cardiovascular risk . In contrast , several study show introduction insulin treatment type 2 diabetic patient intact proinsulin level plasma PAI 1 level decline , indicate beta cell protection , also antiatherogenic property insulin . In recent study , show treatment basal insulin combination metformin effectively reduce intact proinsulin level , insulin glargine superior NPH insulin control postprandial release intact proinsulin entire day . Recently new therapeutic concept use DPP IV inhibitor combination metformin introduce treatment type 2 diabetic patient . There evidence , beta cell , DPP IV Inhibitors might improve conversion intact Proinsulin Insulin C-peptide thereby reduce circulate intact proinsulin level . Since number type 2 diabetic patient treat DPP-IV inhibitor steadily increase , need generate data postprandial release intact proinsulin patient treat DPP-IV inhibitor compare Insulin sulfonylurea treatment . The rationale study investigate effect glargine metformin treatment compare sulfonylurea metformin treatment compare DPP-4 inhibitor metformin treatment postprandial intact proinsulin release postprandial PAI-1 level . Accompanying comparison postprandial intact proinsulin release time course postprandial PAI-levels three antidiabetic treatment group non-diabetic control group perform well .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Inclusion criterion applicable T2DM group : 1.1 . Type 2 diabetes mellitus 1.2 . Duration T2DM 3 15 year inclusively 1.3 . HbA1c 7.5 % inclusively 1.4 . Treated LANTUS+MET ( Group LANTUS+MET ) SU+MET ( Group SU+MET ) DPP4+MET ( Group DPP4+MET ) respectively past 6 month enter study 1.5 . Treated stable antidiabetic dosage past 3 month enter study 2 . Inclusion criterion applicable healthy subject : 2.1 . Fasting blood glucose £ 100 mg/dl ( 5.6 mmol/l ) 2.2 . Oral Glucose Tolerance Test ( OGTT ) reveal IGT DM Inclusion criterion applicable subject : 3 . Age 4075 year inclusively 4 . BMI 20 35 kg/m2 inclusively 5 . Patient inform consent 1 . Exclusion criterion applicable T2DM group : 1.1 . Type 1 diabetes mellitus 1.2 . Treatment insulin LANTUS past 6 month Group LANTUS+MET kind insulin past 3 month Group SU+MET Group DPP4+MET enter study 1.3 . Treatment kind OAD except MET past 6 month Group LANTUS+MET kind OAD except MET+SU past 3 month Group SU+MET kind OAD except DPP4+SU past 3 month Group DPP4+MET enter study 1.4 . Major micro macro vascular complication judge investigator 2 . Exclusion criterion applicable healthy subject : 2.1 . Type 1 type 2 diabetes mellitus ( check oGTT ) 2.2 . Impaired Glucose Tolerance ( IGT , check oGTT ) 2.3 . Impaired Fasting Glucose ( IFG , check oGTT ) Exclusion criterion applicable subject : 3 . History drug alcohol abuse within last five year prior screen 4 . History severe multiple allergy 5 . Treatment investigational drug within 3 month prior screen 6 . Progressive fatal disease 7 . Known psychiatric illness 8 . History significant cardiovascular , respiratory , gastrointestinal , hepatic ( ALAT and/or ASAT &gt; 3 time normal reference range ) , renal ( creatinine &gt; 1.1 mg/dl woman &gt; 1.5 mg/dl men ) , neurological , psychiatric and/or haematological disease judge investigator 9 . Pregnancy breast feed 10 . Sexually active woman childbearing potential consistently correctly practice birth control implant , injectables , combine oral contraceptive , hormonal intrauterine device ( IUDs ) , sexual abstinence vasectomise partner 11 . Lack compliance similar reason , accord investigator , preclude satisfactory participation study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Diabetes Mellitus Type 2</keyword>
	<keyword>insulin glargine</keyword>
	<keyword>Metformin</keyword>
</DOC>